WallStreetZenWallStreetZen

NASDAQ: GLTO
Galecto Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their GLTO stock forecasts and price targets.

Forecast return on equity

Is GLTO forecast to generate an efficient return?

Company
-159.37%
Industry
153.19%
Market
81.87%
GLTO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GLTO forecast to generate an efficient return on assets?

Company
-147.27%
Industry
36.07%
GLTO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GLTO earnings per share forecast

What is GLTO's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$14.50
Avg 2 year Forecast
-$19.47
Avg 3 year Forecast
-$29.99

GLTO revenue forecast

What is GLTO's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$21.6M
Avg 2 year Forecast
$77.4M
Avg 3 year Forecast
$26.2M

GLTO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GLTO$2.42N/AN/A
TTNP$3.55N/AN/A
PALI$0.71$23.00+3,148.59%Strong Buy
LIXT$1.24N/AN/A
ARTL$1.02$5.50+439.22%Strong Buy
View Top Biotech Stocks

Galecto Stock Forecast FAQ

What is GLTO's earnings growth forecast for 2025-2027?

(NASDAQ: GLTO) Galecto's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Galecto's earnings in 2025 is -$21,439,000.On average, 2 Wall Street analysts forecast GLTO's earnings for 2025 to be -$19,174,206, with the lowest GLTO earnings forecast at -$23,736,344, and the highest GLTO earnings forecast at -$14,612,067. On average, 2 Wall Street analysts forecast GLTO's earnings for 2026 to be -$25,746,330, with the lowest GLTO earnings forecast at -$47,604,924, and the highest GLTO earnings forecast at -$3,887,735.

In 2027, GLTO is forecast to generate -$39,650,935 in earnings, with the lowest earnings forecast at -$76,048,866 and the highest earnings forecast at -$3,253,003.

If you're new to stock investing, here's how to buy Galecto stock.

What is GLTO's revenue growth forecast for 2027-2030?

(NASDAQ: GLTO) Galecto's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Galecto's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast GLTO's revenue for 2027 to be $28,536,507, with the lowest GLTO revenue forecast at $28,536,507, and the highest GLTO revenue forecast at $28,536,507. On average, 1 Wall Street analysts forecast GLTO's revenue for 2028 to be $102,363,810, with the lowest GLTO revenue forecast at $102,363,810, and the highest GLTO revenue forecast at $102,363,810.

In 2030, GLTO is forecast to generate $34,645,806 in revenue, with the lowest revenue forecast at $34,645,806 and the highest revenue forecast at $34,645,806.

What is GLTO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: GLTO) forecast ROA is -147.27%, which is lower than the forecast US Biotechnology industry average of 36.07%.

What is GLTO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: GLTO) Galecto's current Earnings Per Share (EPS) is -$18.53. On average, analysts forecast that GLTO's EPS will be -$14.50 for 2025, with the lowest EPS forecast at -$17.95, and the highest EPS forecast at -$11.05. On average, analysts forecast that GLTO's EPS will be -$19.47 for 2026, with the lowest EPS forecast at -$36.00, and the highest EPS forecast at -$2.94. In 2027, GLTO's EPS is forecast to hit -$29.99 (min: -$57.51, max: -$2.46).

What is GLTO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: GLTO) forecast ROE is -159.37%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.